# Hidehisa Saeki

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hidehisa-saeki/

## Facts

| Field | Value |
| --- | --- |
| Citations | 13,209 |
| Field | Dermatology and Skin Diseases |
| h-index | 57 |
| i10-index | 234 |
| Last Known Institution | Nippon Medical School |
| OpenAlex ID | https://openalex.org/A5024531277 |
| ORCID iD | 0000-0002-1095-0355 |
| Works | 606 |

## Researcher papers

- [Cutting Edge: Secondary Lymphoid-Tissue Chemokine (SLC) and CC Chemokine Receptor 7 (CCR7) Participate in the Emigration Pathway of Mature Dendritic Cells from the Skin to Regional Lymph Nodes](https://scholariq.org/papers/cutting-edge-secondary-lymphoid-tissue-chemokine-slc-and-cc-chemokine-receptor-7/)
- [Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*](https://scholariq.org/papers/tralokinumab-for-moderate-to-severe-atopic-dermatitis-results-from-two-52-week/)
- [Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity](https://scholariq.org/papers/thymus-and-activation-regulated-chemokine-in-atopic-dermatitis-serum-thymus-and/)
- [Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population](https://scholariq.org/papers/genome-wide-association-study-identifies-eight-new-susceptibility-loci-for/)
- [Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases](https://scholariq.org/papers/thymus-and-activation-regulated-chemokine-tarc-ccl17-and-skin-diseases/)
- [Guidelines for management of atopic dermatitis](https://scholariq.org/papers/guidelines-for-management-of-atopic-dermatitis/)
- [Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study](https://scholariq.org/papers/delgocitinib-ointment-a-topical-janus-kinase-inhibitor-in-adult-patients-with/)
- [Japanese guidelines for atopic dermatitis 2020](https://scholariq.org/papers/japanese-guidelines-for-atopic-dermatitis-2020/)
- [Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (<scp>UNCOVER</scp>‐J)](https://scholariq.org/papers/efficacy-and-safety-of-ixekizumab-treatment-for-japanese-patients-with-moderate/)
- [Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris](https://scholariq.org/papers/interleukin-12-p40-gene-il12b-3-untranslated-region-polymorphism-is-associated/)
- [The disease burden of pediatric patients with atopic dermatitis in Japan](https://scholariq.org/papers/the-disease-burden-of-pediatric-patients-with-atopic-dermatitis-in-japan/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)

## Researcher university

- [Nippon Medical School](https://scholariq.org/institutions/nippon-medical-school/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.